07 Mar

Personalised Medicine and the Big Data Challenge – 28 March 2018, Brussels, Belgium

[Source: Research & Innovation] The Brussels-based European Alliance for Personalised Medicine (EAPM), sixth annual Presidency conference, which will take place under the auspices of the Bulgarian Presidency of the European Union March 28th 2018, entitled ‘Personalised Medicine and the Big Data Challenge’.
This will take place in the Belgian capital, at the prestigious Bibliothèque Solvay, close to the Brussels seat of the European Parliament.
As was the case last year, the conference will be highly interactive with roundtable sessions and several Q and A opportunities to enhance involvement from the floor. The mix of its members provides extensive scientific, clinical, caring and training expertise in personalised medicine and diagnostics, across patient groups, academia, health professionals and industry.
Relevant departments of the Commission have observer status, as does the EMA. This conference, albeit under the Big Data umbrella, will also have a focus on disease areas and see the following sessions among others:

• Broad picture of profiling/genomics/personalised healthcare
• More data to treat more diseases
• Commissioners’ discussions
• Haematology/Oncology
• How can the region and national level integrate this

07 Mar

Nonprofit Odylia Wants to Resurrect Stranded Gene Therapies

Luk Vandenberghe calls it a “sad irony.”

After decades of ups and downs, gene therapy, which offers a long-lasting genetic fix for a disease, has arrived. A product from Spark Therapeutics called Luxturna, for a rare, inherited type of vision loss, recently became the first-ever approved gene therapy in the U.S., adding to two others in Europe. More products are likely on the way.

And yet Vandenberghe (pictured), the co-director of the Grousbeck Gene Therapy center at Massachusetts Eye and Ear, and his colleagues saw one investor or company after another pass on what they feel could very well be the… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

06 Mar

EnsoData Raises $1.5M to Develop A.I.-powered Sleep Analysis Tools

An estimated 18 million patients in the U.S. suffer from sleep apnea, a major contributor to the “epidemic” of Americans not getting enough sleep, according to the Centers for Disease Control and Prevention.

Sleep apnea-interruptions in breathing that can be caused by obstructions such as the tonsils-is a progressive disorder that can be life-threatening. But before doctors choose a treatment for a patient who doesn’t sleep well, they must figure out whether the patient suffers from sleep apnea or a different disorder. The process of diagnosis, however, tends to be time- and labor-intensive, says Chris Fernandez, co-founder and CEO of… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

06 Mar

“COST European Cooperation in Science and Technology – Info Day in Romania” – 16 March 2018, Cluj-Napoca, Romania

[Source: Research & Innovation] The objective of the event is to provide information to Romanian scientific community about the COST framework, namely its international cooperation approach and explain COST activities as well as how to participate in them.

06 Mar

BIO at 25 – A View of the Past; a Glimpse into the Future

In recognition of BIO’s 25th anniversary, BIO CEO and President, Jim Greenwood sat down with two early champions to talk about what triggered the formation of the organization and what we can learn from the past to help shape the future. That future is envisioned by BIO’s current chair, Dr. John Maraganore in a third video.

First up is Fred Frank, the first life sciences specialist in investment banking. In a career spanning nearly 60 years, Frank served as the lead underwriter in more than 125 initial public offerings. He negotiated more than 75 mergers and acquisitions, including some of the largest and most important transactions in the history of biotechnology.

Next Greenwood looks back to 1993-the year BIO was established-with Robert Beckman, one of the founding members.  Beckman is currently a managing partner at The Channel Group which provides management consulting services to life sciences companies.

After talking about where BIO came from, Greenwood talked about where we are going with Dr. John Maragaore, BIO’s current chair and CEO of Alnylam Pharmaceuticals, Inc. Maraganore has led a career pursuing therapies to address unmet medical needs. At Alnylam Pharmaceuticals, Maraganore is helping lead the development of RNAi therapeutics which aim to address genetic medicines, cardio-metabolic diseases and hepatic infectious diseases.

06 Mar

Why Nike’s refreshed product pages improve CX (& beat Adidas)

Nike has recently refreshed its product pages on its ecommerce store.

There are some key changes which are worth a look…

Read more…

05 Mar

Secretary Azar Talks Opioid Strategy with NGA

Recently, HHS Secretary Alex Azar joined the National Governors Association to discuss opioid addiction and abuse in America. While we can all agree that there is no silver bullet to solving this problem, Secretary Azar outlined several proposals – consistent with recommendations BIO recently released – that the public and private sectors can take to help prevent opioid use disorders in current and future generations.

Understand the Foundations of Pain and Addiction

“We have to understand this crisis in order to stop it,” Azar noted, which BIO has also identified as the first step in moving forward. Before we can develop novel, safer treatments, we must better understand the biology underlying pain and addiction. Government entities like the National Institutes of Health (NIH) can advance basic research which allow for health care professionals, as well as biopharmaceutical innovators, to better understand how to safely treat and manage pain and addiction.

Utilize Resources from the Public and Private Sectors

“We clearly need more tools to help us win this fight, which is why HHS supports cutting edge research on pain and addiction … The potential advances we’re seeing at NIH and in the private sector-like non-addictive painkillers and new methods of addiction treatment-are incredible,” Azar added.

It’s true: many promising, innovative treatments are under development that have the potential to transform the standard of care for pain and addiction. For example, scientists have created an injectable that treats knee pain using capsaicin, a by-product produced of chili peppers; and new therapies that target the body’s peripheral nervous system to treat pain without inducing addictive side effects are on the horizon.

Yet while the future is bright, we must do more. A new report from BIO shows that there isn’t the same level of investment committed to pain and addiction research as there are for other diseases that also inflict a heavy toll on patients and society. For example, the oncology pipeline currently has 2,671 total active clinical programs – that’s more than 10 times the number found in the pain pipeline (220).

That’s why we’ve recommended several policies that will stimulate research and development of innovative treatments that effectively treat pain and opioid addiction and prevent abuse, including modernizing drug development and review processes.

Break Barriers and Expand Access to Safer, Novel Treatments

“People in communities all across America-in our own cities and towns-are alive today because of the progress that has been made in making drugs like naloxone available when and where they’re needed. … [W]e’re committed to working with you to ensure communities have access to these lifesaving drugs,” Azar told the group.

He also noted that, “Medication-assisted treatment works. The evidence on this is voluminous and ever growing.” We couldn’t agree more.

Unfortunately, not all patients have access to the same medicines and cures. As we see time and time again, restrictive insurance coverage and reimbursement policies are often standing between patients and the  most appropriate pain and addiction treatment. As we’ve pointed out before, we must break the barriers that impede patients’ access to the most appropriate treatments – including medication assisted treatment – and stimulate the development of novel and safer therapies to manage this growing public health crisis.

At BIO, we are committed to developing innovative solutions that will allow for an America free of prescription opioid addiction. Learn about our efforts here and check out our refreshed Toolkit for Advocates to find the latest materials and resources on this important issue.

05 Mar

Blue Growth

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-BG-2018-2020Pillar: Societal ChallengesOpening Date: Deadline: Tue, 13 Feb 2018 17:00:00 (Brussels local time)Modification Date: Mon, 5 Mar 2018Latest information: An overview of the number of proposals submitted is now available under the ‘Topic conditions & documents’ section on the topic page.

05 Mar

Unum, Homology Plan IPOs, as Unum Reveals Two Patient Deaths

Two Boston-area biotech startups are shrugging off the recent stock market volatility as they press forward with plans for initial public stock offerings. Genetic therapies company Homology Medicines and cell therapy developer Unum Therapeutics each filed IPO paperwork with regulators late Friday. Unum’s filing revealed that two patients died in a Phase 1 trial late last year. The FDA placed a hold on the trial in December and lifted it last month.

Homology set a preliminary goal of raising $100 million. The Bedford, MA, company has applied for a listing on the Nasdaq Global Market under the stock symbol “FIXX.” Unum,… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

05 Mar

Innovest Global Inc. to Launch Biotech and Health Sciences Division Led by World Renowned …

CLEVELAND, March 05, 2018 (GLOBE NEWSWIRE) — Innovest Global Inc. (OTC PINK:IVST) is pleased to announce that it has tapped Dr. Dwain Morris-Irvin, PhD MPH, to launch a Biotechnology and Health Sciences division for Innovest this spring, to be headquartered in Los Angeles, CA.